Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.

ABSTRACT:

Importance

A blood-based screening tool for detecting diffuse glioma is necessary to improve clinical outcomes.

Objectives

To establish models using serum microRNAs to distinguish patients with diffuse glioma from control individuals without cancer (the Glioma Index) and to differentiate glioblastoma (GBM), primary central nervous system lymphoma (PCNSL), and metastatic brain tumors (the 3-Tumor Index).

Design, setting, and participants

This retrospective, case-control diagnostic study included 157 patients with diffuse glioma and 109 patients with central nervous system (CNS) diseases other than diffuse glioma diagnosed from August 1, 2008, through May 1, 2016, and 314 sex- and age-matched controls without cancer. Samples of patients with diffuse glioma and controls

SUBMITTER: Ohno M 

PROVIDER: S-EPMC6902771 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature